| OVARIAN Non-commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| ADRAPAC/ CEEGOG OX-03 documents available here |
Symptomatic Ascites Drainage with a Patient-controlled Vascular Catheter The target size of the group: 170 subjects |
Ongoing |
| MITO33/ ENGOT-ov51 |
A Randomized phase III trial on Niraparib-TSR 042 vs physician’s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment The target size of the group: 427 subjects |
Ongoing |
| ENGOT-ov78/ SALVOVAR/GINECO | A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor unfavorable primary chemosensitivity and incomplete debulking surgery The target size of the group: 715 subjects |
Under preparation |
| GHOST/ENGOT | A study evaluating the role of post surgery systemic therapy in upfront or relapsed setting in patients with aGCTs The target size of the group: 150 subjects |
Under preparation |
| LEPRE/MANGO | Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial The target size of the group: 132 subjects |
Under preparation |
Rare Cancers in Gynecologic Oncology/ENGOT Registry |
A multi-center, retrospective and prospective observational study based on the collection of data related to patients with rare gynecological neoplasms | Under preparation |
| AGO-OVAR 28/ENGOT-ov57 | Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) The target size of the group: 970 subjects |
Under preparation |
| ENGOT-ov62/ N-PLUS | A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high-grade ovarian cancer patientSin first line therapy The target size of the group: 640 subjects |
Under preparation |
| ENGOT-ov74 /Swiss-GO-7/LoRiO | Localized Radiotherapy with concurrent Olaparib in platinum-sensitive recurrent Ovarian cancer vs. standard of care: a randomised multicentre phase II trial (LoRiO) The target size of the group: 90 subjects |
Under preparation |
| HE4-FU-OVCA/ CEEGOG OX-01 documents available here |
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer A prospective multicentre observational study The target size of the group: 150 subjects |
Closed |
| ATALANTE/ ENGOT-ov29/GINECO |
A randomized, double blinded, phase III study of Atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and Bevacizumab The target size of the group: 600 subjects |
Closed |
| EXPRESSION VI/ ENGOT-ov40/NOGGO S13 |
Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer The target size of the group: 100-200 subjects per participating country |
Closed |
| SOLERO/ ENGOT-OV64/NSGO-CTU |
An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer The target size of the group: 105 subjects |
Preparation terminated |
| CERVICAL Non-commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| RECER/CEEGOG CX-07 | Regression of severe cervical precancerous lesions and associated risk factors The target size of the group: 300 subjects |
Ongoing |
| RACE/ CEEGOG CX-06 documents available here |
Rare cervical tumour study The target size of the group: 300+ subjects |
Ongoing |
| CERVANTES/ CEEGOG CX-05/ ENGOT-cx16 |
An international randomised trial of radical surgery followed by adjuvant (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer patients The target size of the group: 514 subjects |
Ongoing |
| PAROLA/ENGOT-cx18/GINECO | PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer The target size of the group: 510 subjects |
Under preparation |
| SENTICOL III/ ENGOT-cx4/GINECO |
International validation study of sentinel node biopsy in early cervical cancer The target size of the group: 950 subjects |
Enrollment closed |
| COREPEX | COmplications and REcurrence after Pelvic EXenteration: A retrospective multicenter cohort study. The target size of the group: 400 subjects | Closed |
| SENTIX/ CEEGOG CX-01/ ENGOT-cx2 documents available here |
Sentinel node in cervix cancer A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer The target size of the SLN Study group: 600 subjects The target size of the Control group: 100 subjects Estimated enrollment period: 2016 – 2020 |
Closed |
| FERTISS/ CEEGOG CX-03/ ENGOT-cx14 documents available here |
FERTIlity Sparing Surgery in cervical cancer patients outside controlled trials | Closed |
| RSS-EAC-PAT/ CEEGOG CX-04 documents available here |
The Risk Stratification System for endocervical adenocarcinoma based on tumor pattern and its clinical outcomes | Closed |
| ABRAX/ CEEGOG CX2/ ENGOT-cx3 documents available here |
Oncological outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of LN positivity | Closed |
| CoNteSSa/NeoCon-F | FIGO 2018 stage IB2(≥2cm ≤4cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa)/ Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F) The target size of the group: 90 subjects |
Preparation terminated |
| ENDOMETRIAL Non-commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| RAINBO MMRd-GREEN /ENGOT-en14/DGOG | Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - MMRd-GREEN An international, open-label, phase 3 trial that randomly assigns (1:1) patients to receive either adjuvant durvalumab in combination with and following radiotherapy, or standard adjuvant radiotherapy alonewith or without platinum-based chemotherapy. The target size of the group: 316 subjects |
Ongoing |
| EXPRESSION XI/ ENGOT-en16/NOGGO S22 |
IMPROVE -International Survey for Endometrial Cancer patients: perspective and expectation on therapy and quality of life(Expression XI) The target size of the group: 200 subjects per participating country |
Ongoing |
| RAINBO-p53abnRED/ENGOT-en14/GINECO | Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED A randomized phase III trial testing maintenance olaparib versus observation after adjuvant chemoradiation for p53abn endometrial cancer The target size of the group: 526 subjects |
Under preparation |
| STREAM-I/ENGOT-en22/ AGO | Evaluation of preoperative clinical and translational selection criteria for cytoreductive surgery in endometrial cancer: A retrospective multicenter trial with an accompanying translational project The target size of the group: 800 subjects |
Under preparation |
| PORTEC-4a | Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer The target size of the group: 450 subjects |
Enrollment closed |
| ENGOT-EN2-DGCG/ EORTC 55102 |
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer The target size of the group: 240 subjects |
Enrollment closed |
| TESLA1/ CEEGOG EX-02 documents available here |
Tracers for Endometrial cancer Sentinel node LAbelling A Prospective observational study on sentinel node biopsy using two concurrent labelling techniques (radioactive tracer with/without blue dye vs. indocyanin green-ICG) in early-stage endometrial cancer patients The target size of the group: 83 subjects |
Closed |
| REGYS/CEEGOG EX-03 documents available here |
Rare gynecological sarcoma study The target size of the group: 782 subjects |
Closed |
| SALVAGE/ CEEGOG EX01 documents available here |
A retrospective trial on patients who have undergone salvage surgery for a recurrent uterine or cervical cancer Salvage database – data from 620 patients collected |
Closed |
| OVARIAN Commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| REJOICE/ENGOT-ov77/ GINECO |
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers The target size of the group: 555 subjects |
Ongoing |
| GLORIOSA/ENGOT-ov76/MITO | A Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab The target size of the group: 418 subjects |
Ongoing |
| REFRaME-O1/ENGOT-ov79/GEICO | A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) The target size of the group: 600 subjects |
Under preparation |
| EvoPAR‑Ovarian01/|ENGOT-ov82/GINECO | A Phase III, Randomized, Double blind, Placebo-controlled, Multicenter, 3-cohort Study of Saruparib Second line Maintenance Therapy in Patients with Platinum Sensitive Relapsed Ovarian Cancer, with and without BRCAm who Progressed After First-line PARPi The target size of the group: 570 subjects |
Under preparation |
| ENGOT-ov83/ TORL123-002/NOGGO | A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6) The target size of the group: 180 subjects |
Under preparation |
| ENGOT-ov84//MK-2870-022/GEICO | A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer The target size of the group: 750 subjects |
Under preparation |
| ENGOT-ov85/MK-2870-021/GINECO | A Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinumbased Chemotherapy The target size of the group: 900 subjects |
Under preparation |
| RAINFOL-OV2/ENGOT-ov86/ AGO-A |
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer The target size of the group: 530 subjects |
Under preparation |
| DESTINY-OVARIAN-01/ENGOT-ov89/GEICO | A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer The target size of the group: 562 subjects |
Under preparation |
| EPIK-O/ ENGOT-ov61/GEICO |
A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer The target size of the group: 358 subjects |
Enrollment closed |
| BOUQUET/ ENGOT-GYN2/GINECO |
A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors The target size of the group: 80-200 subjects |
Enrollment closed |
| ARTISTRY-7/ ENGOT-ov68/NOGGO |
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer The target size of the group: 376 subjects |
Enrollment closed |
| ROSELLA/ CORT125134-556/ ENGOT-ov72/MITO |
A Phase III trial evaluating the efficacy of Relacoritant in combination with Nab-Paclitaxel in the treatment of advanced, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer patients The target size of the group: 360 subjects |
Enrollment closed |
| MER-XMT-1536-1/ UPLIFT/ ENGOT-ov67/AGO-A |
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b The target size of the group: 180 to 240 subjects |
Enrollment closed |
| MIRASOL/ ENGOT-ov55/BGOG |
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression The target size of the group: 430 subjects |
Enrollment closed |
| MK-7339-001-00/ ENGOT-ov43/BGOG |
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) The target size of the group: 1367 subjects |
Enrollment closed |
| INNOVATE-3/ ENGOT-ov50/BGOG |
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC) The target size of the group: 540 subjects |
Enrollment closed |
| FIRST/ ENGOT-ov44/GINECO |
A Patient‑centric, Randomized, Phase 3 comparison of Platinum‑based Therapy with or without bevacizumab to the same plus TSR‑042 as first‑line treatment of stage iii or iv non-mucinous ovarian cancer followed by maintenaNce therapy The target size of the group: 720 - 960 subjects |
Enrollment closed |
| ATHENA/ ENGOT-ov45/NCRI |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy The target size of the group: 1000 subjects |
Enrollment closed |
| IMAGYN050/ YO39523/GOG-3015/ ENGOT-ov39 |
A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer The target size of the group: 1300 subjects |
Enrollment closed |
| PRIMA/ ENGOT-ov26/GEICO/1509 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Studyof Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy The target size of the group: 620 subjects |
Enrollment closed |
| SOTIO/ SOV01 |
SOV01 A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma The target size of the group: additional 30 subjects |
Closed |
| SOTIO/ SOV06 |
SOV06 An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma The target size of the group: 30 subjects |
Closed |
| JAVELIN OVARIAN 200 | A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer Approximately 550 patients will be randomized |
Closed |
| SOTIO/ SOV02 |
SOV02 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed platinum sensitive epithelial ovarian carcinoma | Closed |
| SOTIO/ SOV03 |
SOV03 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial ovarian carcinoma | Closed |
| MILO/ ENGOT-ov11/BGOG |
MEK Inhibitor in Low-grade Serous Ovarian Cancer A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum |
Closed |
| NOVA/ ENGOT-ov16/NSGO |
Niraparib in OVArian cancer A randomized, double-blind phase 3 trial of maintenance with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer |
Closed |
| AVB500-OC-004/ ENGOT-ov66/GEICO |
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer The target size of the group: 300 to 500 subjects |
Study early termination |
| ENGOT-ov73/LUPPA-1/GINECO | A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Ovarian Cancer The target size of the group: 250 subjects |
Preparation terminated |
| SOV09/VITALIA/ ENGOT-ov53/CEEGOG |
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma The target size of the group: 678 subjects |
Preparation terminated |
| CERVICAL Commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| GCT1015-05/ ENGOT-cx8/BGOG |
A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer The target size of the group: 140 subjects |
Enrollment closed |
| KEYNOTE-A18/ ENGOT-cx11/MITO |
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer The target size of the group: 980 subjects |
Enrollment closed |
| GCT1015-07/ ENGOT-cx12/BGOG |
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer The target size of the group: 486 subjects |
Enrollment closed |
| GCT1015-04/ ENGOT-cx6/BGOG |
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®‑TF‑ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer The target size of the group: 100 subjects |
Enrollment closed |
| FERMATA/ ENGOTcx13/AGO |
An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer The target size of the group: 316 subjects |
Preparation terminated |
| BRAVA/ ENGOT-cx17/GINECO |
A Phase 3 Trial of Balstilimab versus Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer after Platinum-Based Chemotherapy The target size of the group: 486 subjects |
Preparation terminated |
| ENDOMETRIAL Commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| ENGOT-EN23/MK-2870-005/ MITO |
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy The target size of the group: 710 subjects |
Ongoing |
| ENGOT-EN20/ GOG-3083/ XPORT-EC-042/BGOG |
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 WildType, Advanced or Recurrent Endometrial Carcinoma The target size of the group: 220 subjects |
Ongoing |
| ENGOT-EN26/MANGO | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy The target size of the group: 520 subjects |
Under preparation |
| DESTINY/ENGOT-EN24/NSGO | An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer The target size of the group: 480 subjects |
Under preparation |
| ENGOT-EN25/BNT323-01/NSGO | A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer The target size of the group: 420 subjects |
Under preparation |
| KEYNOTE-C93/ GOG-3064/ ENGOT-en15/MITO |
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting The target size of the group: 350 subjects |
Enrollment closed |
| POD1UM-204/ INCMGA 0012-204/ ENGOT-EN12/NOGGO |
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial CancerWho Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) The target size of the group: 300 subjects |
Enrollment closed |
| RUBY/ ENGOT EN-6/NSGO |
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY) The target size of the group (PART I): 470 subjects The target size of the group (PART II): 270 subjects |
Enrollment closed |
| KEYNOTE-B21/ ENGOT-en11/BGOG | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent The target size of the group: 990 subjects |
Enrollment closed |
| DUO-E/ ENGOT EN-10/BGOG |
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumabwith or without Olaparibin Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer The target size of the group: 699 subjects |
Enrollment closed |
| SIENDO/ ENGOT-EN5/BGOG-EN5 |
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer. The target size of the group: 248 subjects |
Enrollment closed |
| ENGOT-en21/KRT-232-118/AGO-A | A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy The target size of the group: 268 subjects |
Study early termination |
| ENGOT-en17/EQ132-303/GOG-3075/GINECO | A Randomized, Double-Blinded, Placebo-Controlled Phase 3 Study of EQ132 (Lerociclib) with Letrozole, versus Placebo in Combination with Letrozole, in Participants with Advanced or Recurrent Grade 1 or 2 Endometrioid Endometrial Carcinoma The target size of the group: 320 subjects |
Preparation terminated |